Condition
Malignant Pleural Mesothelioma
Estimated Enrollment: 0
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
Study ID Numbers: UCL/08/0359|2009-013638-26
Study First Received: May 11, 2011
Last Updated: March 21, 2012
Estimated Primary Completion Date: null
Primary Outcome Measures:
Phase I only – Dose-limiting toxicities|Phase I only – Number of cycles of pemetrexed-cisplatin given|Phase II only – Progression free survival
Sponsors and Collaborators:
University College, London|Merck Sharp & Dohme Corp.
Website Link: https://ClinicalTrials.gov/show/NCT01353482
